Beck AT, Baruch E, Balter JM, Steer RA, Warman DM A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res. 2004 Jun 1;68(2-3):319-29. doi: 10.1016/S0920-9964(03)00189-0.
Bruno N, Sachs N, Demily C, Franck N, Pacherie E Delusions and metacognition in patients with schizophrenia. Cogn Neuropsychiatry. 2012;17(1):1-18. doi: 10.1080/13546805.2011.562071. Epub 2011 Jun 28.
Calcagni A, Lombardi L, Sulpizio S Analyzing spatial data from mouse tracker methodology: An entropic approach. Behav Res Methods. 2017 Dec;49(6):2012-2030. doi: 10.3758/s13428-016-0839-5.
Charles L, Gaillard R, Amado I, Krebs MO, Bendjemaa N, Dehaene S Conscious and unconscious performance monitoring: Evidence from patients with schizophrenia. Neuroimage. 2017 Jan 1;144(Pt A):153-163. doi: 10.1016/j.neuroimage.2016.09.056. Epub 2016 Sep 23.
Chaumon M, Bishop DV, Busch NA A practical guide to the selection of independent components of the electroencephalogram for artifact correction. J Neurosci Methods. 2015 Jul 30;250:47-63. doi: 10.1016/j.jneumeth.2015.02.025. Epub 2015 Mar 16.
Chiu CY, Liu CC, Hwang TJ, Hwu HG, Hua MS Metamemory in patients with schizophrenia measured by the feeling of knowing. Psychiatry Res. 2015 Dec 15;230(2):511-6. doi: 10.1016/j.psychres.2015.09.046. Epub 2015 Oct 3.
Fleming SM, Dolan RJ, Frith CD Metacognition: computation, biology and function. Philos Trans R Soc Lond B Biol Sci. 2012 May 19;367(1594):1280-6. doi: 10.1098/rstb.2012.0021.
Fox, J (2003). Effect displays in R for generalised linear models. Journal of statistical software 8(15): 1-27.
Kay SR, Fiszbein A, Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
Kepecs A, Mainen ZF A computational framework for the study of confidence in humans and animals. Philos Trans R Soc Lond B Biol Sci. 2012 May 19;367(1594):1322-37. doi: 10.1098/rstb.2012.0037.
Kieslich, P J., D. U. Wulff, et al. Mousetrap: An R package for processing and analyzing mouse-tracking data (Version 3.0.0). 2017
Maniscalco B, Lau H A signal detection theoretic approach for estimating metacognitive sensitivity from confidence ratings. Conscious Cogn. 2012 Mar;21(1):422-30. doi: 10.1016/j.concog.2011.09.021. Epub 2011 Nov 8.
Morey, R D., J. N. Rouder, et al. BayesFactor: Computation of Bayes factors for common designs. R package version 0.98. 2014.
Moritz S, Woodward TS, Jelinek L, Klinge R Memory and metamemory in schizophrenia: a liberal acceptance account of psychosis. Psychol Med. 2008 Jun;38(6):825-32. doi: 10.1017/S0033291707002553. Epub 2008 Jan 21.
Nasrallah H, Morosini P, Gagnon DD Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008 Nov 30;161(2):213-24. doi: 10.1016/j.psychres.2007.11.012. Epub 2008 Oct 11.
Perrin F, Pernier J, Bertrand O, Echallier JF Spherical splines for scalp potential and current density mapping. Electroencephalogr Clin Neurophysiol. 1989 Feb;72(2):184-7. doi: 10.1016/0013-4694(89)90180-6.
Rausch M, Muller HJ, Zehetleitner M Metacognitive sensitivity of subjective reports of decisional confidence and visual experience. Conscious Cogn. 2015 Sep;35:192-205. doi: 10.1016/j.concog.2015.02.011. Epub 2015 Mar 7.
Singmann, H , B. Bolker, et al. afex: Analysis of factorial experiments. R package version 0.15-2. 2015.
Team, R C.R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2016.
Wickham, H ggplot2: elegant graphics for data analysis, Springer. 2016.
Yeung N, Summerfield C Metacognition in human decision-making: confidence and error monitoring. Philos Trans R Soc Lond B Biol Sci. 2012 May 19;367(1594):1310-21. doi: 10.1098/rstb.2011.0416.
Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.